Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
about
Botulinum toxin injections for low-back pain and sciaticaBotulinum toxin for low-back painSpotlight on botulinum toxin and its potential in the treatment of stroke-related spasticitySafety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticityClinical relevance of botulinum toxin immunogenicityA systematic review protocol to evaluate the psychometric properties of measures of function within adult neuro-rehabilitationPractice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headacheDose response with onabotulinumtoxinA for post-stroke spasticity: a pooled data analysis.Temporal characteristics of botulinum neurotoxin therapy.Ixcellence Network®: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection.The Italian real-life post-stroke spasticity survey: unmet needs in the management of spasticity with botulinum toxin type A.The role of activity in synaptic degeneration in a protein misfolding disease, prion diseaseEvaluation of the effects of botulinum toxin A injections when used to improve ease of care and comfort in children with cerebral palsy whom are non-ambulant: a double blind randomized controlled trial.Botulinum toxin: bioweapon & magic drugA double-blind, randomised, crossover trial of two botulinum toxin type a in patients with spasticity.Age specificity in general and rehabilitation medical services in children with cerebral palsyStudy protocol: precision of a protocol for manual intramuscular needle placement checked by passive stretching and relaxing of the target muscle in the lower extremity during BTX-A treatment in children with spastic cerebral palsy, as verified by mOnabotulinumtoxinA muscle injection patterns in adult spasticity: a systematic literature review.Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of theGRIN: "GRoup versus INdividual physiotherapy following lower limb intra-muscular Botulinum Toxin-A injections for ambulant children with cerebral palsy: an assessor-masked randomised comparison trial": study protocol.Development of treatment concepts for the use of botulinum toxin a in children with cerebral palsy.A retrospective study to assess resource utilization in patients with cervical dystonia in the United Kingdom.Kinematic improvement following Botulinum Toxin-A injection in upper-limb spasticity due to strokeFactors influencing goal attainment in patients with post-stroke upper limb spasticity following treatment with botulinum toxin A in real-life clinical practice: sub-analyses from the Upper Limb International Spasticity (ULIS)-II StudyA practical approach to management of focal hand dystoniaPhysical therapies as an adjunct to Botulinum toxin-A injection of the upper or lower limb in adults following neurological impairment.Long-term efficacy and safety of incobotulinumtoxinA and conventional treatment of poststroke arm spasticity: a prospective, non-interventional, open-label, parallel-group study.Botulinum Toxin Type A Injection for Spastic Equinovarus Foot in Children with Spastic Cerebral Palsy: Effects on Gait and Foot Pressure Distribution.Botulinum toxin effects on gasatrocnemius strength and plantar pressure in diabetics with peripheral neuropathy and forefoot ulceration.Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticityBotulinum toxin injection and phenol nerve block for reduction of end-of-life painOnabotulinumtoxinA (botulinum toxin type-A) in the prevention of migraine.Marine natural product drug discovery: Leads for treatment of inflammation, cancer, infections, and neurological disorders.Effects of botulinum toxin A on calf muscles in children with cerebral palsy: a systematic review.Targeted secretion inhibitors-innovative protein therapeuticsAbo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.The efficacy of Botulinum Toxin A for spasticity and pain in adults: a systematic review and meta-analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach.Diffusion, spread, and migration of botulinum toxin.Botulinum toxin for neuropathic pain and spasticity: an overview.Botulinum toxin for symptomatic therapy in multiple sclerosis.
P2860
Q24234725-F84BC59A-B1C2-4F0B-837E-5070EA879E8DQ24241281-89CD69F9-2F55-4F83-9CD4-2DDF4E4D9164Q26750450-76761680-5F5C-4802-9E2C-FDC53B7FDCDEQ26766544-001D0245-1D36-441F-AF5A-0BC470309833Q26824771-635C9A81-F7FA-48FF-9D52-E56E28FCA5A0Q28082115-8F4201E5-EE96-49C8-AE9C-14C19B519B0BQ29392461-1DCBA079-32A4-4AF3-A650-F8E757A85226Q33723150-A1720891-CEEB-4407-92B7-62033DFCCB2AQ33740588-1097F9CB-FBDF-4BFC-9FD7-555F2609140BQ33897459-34EDD6A7-2DE1-4379-BBD5-45CA6A627E2FQ33897481-1B4EBAC4-E1AF-459E-B6B1-C5DB2AA935B9Q34345796-ACEA4F20-4BEB-433B-AC48-5673F65E4EC6Q34371274-F22DE235-CFAF-4679-B47F-4C28292A2B09Q34530009-10716E5D-78DF-49AD-B30F-1E882C7D6995Q34611482-ADB667A0-2FCF-41EE-9832-1925ED381DD8Q34791558-876241B8-F8A7-44C4-9D5C-4DC942CBF8D0Q34966160-7851C2C6-0A81-486D-A7CD-189FA37AC940Q34980467-FE83B537-B127-4052-9E74-FDC77722A754Q35065448-354BB436-FEFB-4471-8DAB-604ACCA633D3Q35087305-FB064626-A43C-4FB0-AE86-6ABBB2D2A0B2Q35155959-66088EBF-866D-4097-B3AF-9D8598D86B46Q35173327-339D8528-DC38-4CE5-8D6A-669897E76684Q35185960-3364DCAB-3A8E-4261-BB56-3100BF2B0493Q35564045-4A6514A7-DEB5-4A3D-BA8E-F861031C1B43Q35651809-98343F84-7133-4D4F-8936-FFAA33D39325Q36209475-B6AFF1CE-F716-44EC-A249-73151153608BQ36456943-C20B10DE-CE25-4FDD-BDFD-AC3DBE767B2CQ36541635-08198793-C75B-41B3-B638-812ABC45F3A1Q37106629-B80A8201-36B6-40CE-916E-66188E57FB2BQ37340491-8B48386F-D348-4CB2-8C11-B491E8C8D682Q37403903-66220FD4-4D1E-4A32-9DD7-B8B0598D4ED9Q37678415-259B8C50-67A6-493E-9140-101D93AF34FCQ37742166-8861113D-F93B-4666-AD51-23B3361F392CQ37765760-CFD604AA-EC2B-4F03-BE6C-E80F8F8FFF2EQ37954277-598AE7A1-A826-4880-8D15-26C7B2576245Q38080776-34C25B34-8B89-4146-B149-A052FD7AE6C8Q38122349-88C1CC1E-C6A7-4767-955C-0DCBD1DD745BQ38122648-6F208554-5FDE-45BB-913F-A26B19CE7C19Q38196928-C0D501F9-E4FC-48C8-9E4B-653458C84F67Q38222194-70E859F6-F8CD-4352-AEEC-E8DC76FA91C3
P2860
Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Assessment: Botulinum neurotox ...... American Academy of Neurology.
@en
Assessment: Botulinum neurotoxin for the treatment of spasticity
@nl
type
label
Assessment: Botulinum neurotox ...... American Academy of Neurology.
@en
Assessment: Botulinum neurotoxin for the treatment of spasticity
@nl
prefLabel
Assessment: Botulinum neurotox ...... American Academy of Neurology.
@en
Assessment: Botulinum neurotoxin for the treatment of spasticity
@nl
P2093
P1433
P1476
Assessment: Botulinum neurotox ...... American Academy of Neurology.
@en
P2093
D M Simpson
H K Graham
J M Miyasaki
J-M Gracies
L L Simpson
Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
P304
P356
10.1212/01.WNL.0000311391.00944.C4
P407
P577
2008-05-01T00:00:00Z